Similar articles

• Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage).

  Han KH, Rha SW, Kang HJ, Bae JW, Choi BJ, Choi SY, Gwon HC, Bae JH, Hong BK, Choi DH, Han KR. Han KH, et al. J Clin Lipidol. 2012 Jul-Aug;6(4):340-51. doi: 10.1016/j.jacl.2012.01.009. Epub 2012 Feb 4. J Clin Lipidol. 2012. PMID: 22836071 Clinical Trial.
• Torcetrapib and atorvastatin.

  Shear CL. Shear CL. N Engl J Med. 2005 Oct 6;353(14):1527-9; author reply 1527-9. doi: 10.1056/NEJMc055277. N Engl J Med. 2005. PMID: 16207861 No abstract available.
• Noninferiority of pitavastatin in intravascular ultrasound findings.

  Kaneda H, Ma J, Morita T. Kaneda H, et al. J Am Coll Cardiol. 2010 Jan 19;55(3):262-3; author reply 263. doi: 10.1016/j.jacc.2009.07.065. J Am Coll Cardiol. 2010. PMID: 20117416 No abstract available.
• [Atorvastatin (Lipitor)].

  Carpentier Y, Ducobu J, Sternon J. Carpentier Y, et al. Rev Med Brux. 1999 Oct;20(5):427-33. Rev Med Brux. 1999. PMID: 10582478 Review. French.
• [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-aCS) study].

  Takeuchi T, Ota H, Hasebe N. Takeuchi T, et al. Nihon Rinsho. 2011 Nov;69 Suppl 9:336-40. Nihon Rinsho. 2011. PMID: 22724225 Review. Japanese. No abstract available.